{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:43:05Z","timestamp":1789962185011,"version":"4.0.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Major Science and Technology Innovation Projects in Chengdu","award":["\u00ef\u00bc\u02c6No.2021-YFO8-00119-GX)"],"award-info":[{"award-number":["\u00ef\u00bc\u02c6No.2021-YFO8-00119-GX)"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(No. 32170119)"],"award-info":[{"award-number":["(No. 32170119)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:p>This study aimed to elucidate the resistance trends of <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> isolates from 2005 to 2023 in Zhejiang Province, emphasizing the impact of Coronavirus disease 2019 (COVID-19) on antimicrobial resistance patterns and clinical management. We retrospectively analyzed 7326 <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> isolates collected from diverse clinical sources in a tertiary hospital in Zhejiang Province from 2005 to 2023. Identification and antibiotic susceptibility testing of each isolate were performed using the VITEK-32 automated system and the disk diffusion method, following Clinical and Laboratory Standards Institute guidelines. We assessed resistance patterns for key antibiotic classes relevant to <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> treatment, including carbapenems, \u03b2-lactams, aminoglycosides, and quinolones. Statistical analyses, including trend evaluations and resistance determinant assessments, were conducted in R software (version 4.2.2), with visualizations generated through ggplot2 to illustrate resistance trends over time. This study focused on key anti-pseudomonal agents including carbapenems (imipenem and meropenem), \u03b2-lactams (piperacillin), and quinolones (ciprofloxacin and levofloxacin). We observed a progressive increase in resistance to imipenem from 6.8% in 2005 to 48.2% in 2023 and meropenem from 25.4% to 44.2% over the same period. Conversely, resistance rates to aminoglycosides declined, with gentamicin resistance dropping from 22.0% in 2005 to 5.0% in 2019. Cephalosporins exhibited variable trends, with cefepime resistance peaking at 40.4% in 2013 before declining to 12.1% in 2023. The findings indicated a progressive increase in resistance rates for these antibiotics, with notable peaks coinciding with changes in clinical practices and the COVID-19 pandemic. The analysis demonstrated that shifts in prescription habits, particularly during the COVID-19 pandemic, influenced resistance patterns, underscoring the need for context-specific antimicrobial stewardship strategies. This study identifies significant, evolving resistance patterns in <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> over a 19-year period, with marked increases in resistance to critical antibiotics, including carbapenems (imipenem, meropenem), quinolones (levofloxacin, ciprofloxacin), and certain \u03b2-lactams (piperacillin). These findings underscore an urgent need for dynamic, tailored infection control measures, emphasizing the importance of robust antibiotic stewardship programs, localized treatment guidelines, and proactive monitoring of resistance trends. Implementing these strategies is essential to effectively counter the challenges posed by multi-drug resistant <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>, improve patient outcomes, and sustain the efficacy of vital antibiotic therapies.<\/jats:p>","DOI":"10.1097\/md.0000000000040606","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:03:20Z","timestamp":1732032200000},"page":"e40606","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Trends and implications of antimicrobial resistance in Pseudomonas aeruginosa: Insights from a 19-year study in Zhejiang Province"],"prefix":"10.1097","volume":"103","author":[{"given":"Ju","family":"Li","sequence":"first","affiliation":[{"name":"Key Laboratory of Non-coding RNA and Drug Discovery at Chengdu Medical College of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan China"},{"name":"Department of Stomatology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China"},{"name":"Vincent Mary School of Engineering, Science and Technology, Assumption University of Thailand, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkang","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Non-coding RNA and Drug Discovery at Chengdu Medical College of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan China"},{"name":"Clinical School of Medicine, Chengdu Medical College, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Microbial Drugs Innovation and Transformation, Yan\u2019an University, Yan\u2019an, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical School of Medicine, Chengdu Medical College, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medical Applied Technology, Shenyang Medical College, Shenyang, Liaoning Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Clinical School of Medicine, Chengdu Medical College, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"He","sequence":"additional","affiliation":[{"name":"Clinical School of Medicine, Chengdu Medical College, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Mechanical Engineering, Chengdu University, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1612-1136","authenticated-orcid":false,"given":"Xu","family":"Jia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Non-coding RNA and Drug Discovery at Chengdu Medical College of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan China"},{"name":"School of Basic Medical Sciences, Chengdu Medical College, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3767-0249","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"},{"name":"Department of Pharmacy, Shaoxing People\u2019s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11274-019-2739-1","article-title":"Metabolomic studies of Pseudomonas aeruginosa.","volume":"35","author":"Mielko","year":"2019","journal-title":"World J Microbiol Biotechnol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases.","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0195941700057647","article-title":"Pseudomonas aeruginosa.","volume":"4","author":"Stratton","year":"1983","journal-title":"Infect Control"},{"key":"R4-20250504","first-page":"CD006961","article-title":"Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.","volume":"6","author":"Waters","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of pseudomonas aeruginosa infections: an update.","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"53","DOI":"10.51620\/0869-2084-2022-67-1-53-58","article-title":"Pseudomonas aeruginosa efflux pump superfamily (review of literature).","volume":"67","author":"Ivanov","year":"2022","journal-title":"Klin Lab Diagn"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge.","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa - Mechanisms, epidemiology and evolution.","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist Updat"},{"issue":"6 Suppl 1","key":"R9-20250504","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.03.011","article-title":"Mechanisms of antimicrobial resistance in bacteria.","volume":"119","author":"Tenover","year":"2006","journal-title":"Am J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biotechadv.2018.11.006","article-title":"Quorum sensing inhibitors as antipathogens: biotechnological applications.","volume":"37","author":"Kalia","year":"2019","journal-title":"Biotechnol Adv"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-014-0100-x","article-title":"The hierarchy quorum sensing network in Pseudomonas aeruginosa.","volume":"6","author":"Lee","year":"2015","journal-title":"Protein Cell"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/fmb-2021-0158","article-title":"Pathogenic arsenal of Pseudomonas aeruginosa: an update on virulence factors.","volume":"17","author":"Veetilvalappil","year":"2022","journal-title":"Future Microbiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2013.11.001","article-title":"Pseudomonas aeruginosa biofilm: potential therapeutic targets.","volume":"42","author":"Sharma","year":"2014","journal-title":"Biologicals"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5582\/bst.2016.01020","article-title":"Nosocomial infection and its molecular mechanisms of antibiotic resistance.","volume":"10","author":"Xia","year":"2016","journal-title":"Biosci Trends"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/17460441.2020.1803274","article-title":"Novel therapeutic strategies for treating Pseudomonas aeruginosa infection.","volume":"15","author":"Shao","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ajic.2014.08.006","article-title":"Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care\u2013associated infection control in the hospitals of Southern China: A case-control surveillance study.","volume":"42","author":"Peng","year":"2014","journal-title":"Am J Infect Control"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.2147\/IDR.S408956","article-title":"The distribution, drug susceptibility, and dynamic trends of pseudomonas aeruginosa infection in a Tertiary Hospital in China During 2016\u20132022.","volume":"16","author":"Li","year":"2023","journal-title":"Infect Drug Resist"},{"issue":"suppl_2","key":"R18-20250504","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1093\/cid\/ciy657","article-title":"Current status and trends of antibacterial resistance in China.","volume":"67","author":"Hu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0037-1602583","article-title":"Emergence of antimicrobial resistance among pseudomonas aeruginosa: implications for therapy.","volume":"38","author":"Lynch","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.medin.2022.03.015","article-title":"Treatment of severe multidrug resistant Pseudomonas aeruginosa infections.","volume":"46","author":"D\u00edaz Santos","year":"2022","journal-title":"Med Intensiva (Engl Ed)"},{"key":"R21-20250504","first-page":"93","article-title":"Resistance trends among clinical isolates in China reported from CHINETsurveillance of bacterial resistance, 2005\u20132014.","volume":"17","author":"Hufp","year":"2017","journal-title":"Chin J Infect Chemother"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections.","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"R23-20250504","first-page":"1172","article-title":"Plethora of antibiotics usage and evaluation of carbapenem prescribing pattern in intensive care units: A single-center experience of Malaysian academic hospital.","volume":"11","author":"Lau","year":"2022","journal-title":"Antibiotics (Basel, Switzerland)"},{"issue":"Suppl 1(Suppl1)","key":"R24-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.37201\/req\/s01.11.2021","article-title":"Ceftazidime-avibactam.","volume":"34","author":"Matesanz","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"R25-20250504","first-page":"2170","article-title":"Changing trend in the antibiotic resistance pattern of pseudomonas aeruginosa isolated from wound swabs of out-patients and in-patients of a Tertiary Care Hospital.","volume":"7","author":"Joseph","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jmii.2019.08.017","article-title":"Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period.","volume":"54","author":"Feng","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"R27-20250504","first-page":"377","article-title":"CHINET surveillance of bacterial resistance: results of 2020.","volume":"21","author":"Hu","year":"2021","journal-title":"Chin J Infect Chemother"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.meegid.2013.10.027","article-title":"OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China.","volume":"21","author":"Fang","year":"2014","journal-title":"Infect Genet Evol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcma.2017.08.016","article-title":"Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.","volume":"81","author":"Rostami","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1080\/22221751.2020.1754133","article-title":"Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019).","volume":"9","author":"El-Sayed Ahmed","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance.","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum \u03b2-lactamases, in the thighs of neutropenic mice.","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic strategies for emerging multidrug-resistant Pseudomonas aeruginosa.","volume":"11","author":"Kunz Coyne","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:04:00Z","timestamp":1746320640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":33,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040606","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}